Tag: Emrelis®

This year, the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will feature a breadth of new data on emerging antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), particularly across solid tumors and hematologic malignancies. This article synthesizes pivotal findings from AbbVie’s next-generation ADC and TCE platforms—including SEZ6-, PSMA/STEAP1-, c-Met-, and FRα-targeted ADCs—alongside immune checkpoint inhibitor combinations and real-world evidence.

Economy: Failure to Reshore Pharmaceutical Manufacturing: US Approved Drug Manufacturing Shifts to Europe as US Deal Volume Drops

The US Food and Drug Administration (FDA) has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis®, AbbVie; Previously known as ABBV-399; See Drug description and ADC Drugmap)*, a c-Met-directed antibody-drug conjugates (ADC) for ther treatment of adults patients diagnosed with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein over-expression who received a prior systemic therapy.